Endologix (ELGX) Set to Announce Earnings on Thursday

Share on StockTwits

Endologix (NASDAQ:ELGX) is set to release its earnings data after the market closes on Thursday, November 1st. Analysts expect Endologix to post earnings of ($0.25) per share for the quarter.

Endologix (NASDAQ:ELGX) last posted its quarterly earnings results on Thursday, August 9th. The medical instruments supplier reported ($0.18) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.18). Endologix had a negative net margin of 40.92% and a negative return on equity of 69.06%. The business had revenue of $44.70 million for the quarter, compared to the consensus estimate of $44.43 million. During the same period in the prior year, the business posted ($0.10) earnings per share. Endologix’s revenue for the quarter was down 8.0% compared to the same quarter last year. On average, analysts expect Endologix to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

NASDAQ ELGX opened at $1.20 on Tuesday. Endologix has a 1-year low of $1.09 and a 1-year high of $6.72. The company has a debt-to-equity ratio of 5.37, a quick ratio of 1.20 and a current ratio of 1.90. The firm has a market capitalization of $104.19 million, a PE ratio of -2.50 and a beta of 0.01.

A number of research firms have recently weighed in on ELGX. BidaskClub downgraded shares of Endologix from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 25th. Zacks Investment Research downgraded shares of Endologix from a “hold” rating to a “sell” rating in a research note on Tuesday, October 9th. Oppenheimer set a $4.00 price target on shares of Endologix and gave the stock a “hold” rating in a research note on Friday, August 10th. Piper Jaffray Companies downgraded shares of Endologix from an “overweight” rating to a “neutral” rating in a research note on Friday, August 10th. Finally, Stifel Nicolaus set a $3.00 price target on shares of Endologix and gave the stock a “hold” rating in a research note on Saturday, August 11th. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating and one has assigned a buy rating to the company. Endologix has a consensus rating of “Hold” and an average target price of $3.86.

In other Endologix news, CFO Vaseem Mahboob acquired 30,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 16th. The stock was purchased at an average cost of $2.43 per share, for a total transaction of $72,900.00. Following the completion of the acquisition, the chief financial officer now owns 146,812 shares of the company’s stock, valued at approximately $356,753.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 4.10% of the company’s stock.

About Endologix

Endologix, Inc develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. It offers minimally-invasive endovascular repair (EVAR) products, including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the ovation abdominal stent graft system.

Read More: NASDAQ Stock Market Explained

Earnings History for Endologix (NASDAQ:ELGX)

Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply